Daviripine Vaginal Ring RESULTS of a recently conducted study in the Sub-Saharan region, involving 15 trial sites in Malawi, Uganda, South Africa and Zimbabwe, known as A Study to Prevent Infection with a Ring for Extended Use (ASPIRE), has shown that Anti-Retroviral drugs (ARVs) can protect African women from primary Human Immune Virus (HIV) by 27%, through a virginal davirapine ring for women. The study was conducted by the Microbicide Trials Network (MTN) and was led by Dr. Jared Baeten (University of Washington/USA) and Dr. Thesla Palanee-Phillips (Wits Reproductive Health & HIV Institute/SA). The ring is meant to be placed into the women’s vagina and would produce anti-retroviral drug, preventing women and sexually active young girls from obtaining HIV/AIDS when sleeping with an infected partner. According to the medical officer/sub-investigator of the Aspire study, with the University of California San Francisco (UCSF) and also with the Uni...
Reports on the political spheres ,Democracy, Media Freedom ,Freedom of speech, Gender and Equity, Gays and Lesbian ,Economics, Climate Change,Violence,Health, Renewable Energy